Loading clinical trials...
Loading clinical trials...
An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid
Conditions
Interventions
SEL-212
SEL-037
+1 more
Locations
13
United States
Anaheim Clinical Trials
Anaheim, California, United States
Tri West Research Associates LLC
El Cajon, California, United States
Irvine Center for Clinical Research Inc.
Irvine, California, United States
Clinical Research of West Florida
Clearwater, Florida, United States
Omega Research Consultants LLC
DeBary, Florida, United States
Compass Research LLC
Orlando, Florida, United States
Start Date
October 1, 2016
Primary Completion Date
December 1, 2018
Completion Date
January 1, 2019
Last Updated
February 14, 2022
NCT07116746
NCT06310967
NCT06859073
NCT07002762
NCT06966635
NCT06824376
Lead Sponsor
Selecta Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions